Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2009

View Archived Issues

First pediatric patient treated with Aptocine in neurofibromatosis study

Hana reaches enrollment target for phase II Marqibo trial in ALL

Zilver PTX Drug-Eluting Peripheral Stent receives approval in Europe

Antisoma and Bryan Oncor enter agreement for anticancer drug P-2045

Neurobiological Technologies terminates agreement with Merz and CMCC

Dynavax meets with EMEA for Heplisav HBV vaccine development strategy

FDA accepts to file Theratechnologies' tesamorelin NDA

Kuros reports data with KUR-212 in burn victims requiring mesh grafting

Labopharm submits response to FDA complete response letter for trazodone

Vedrop receives marketing authorization in the European Union

Tolerx amends phase III DEFEND protocol

Anadys reports viral load data for ANA-773 in hepatitis C patients

Avanir presents phase III study results for Zenvia

Anti-bovine thrombin 4A IgG cross-reacts with human thrombin and Recothrom

CB1/CB2 receptor antagonist THCV displays anticonvulsant activity in rat model of epilepsy

Novel antithrombotic agent S-35972 displays promising preclinical activity

Preclinical and early clinical data indicate that EP-42675 is a potent anticoagulant

O-3223 shows potency in preclinical models of inflammatory and neuropathic pain

PF-2341066 displays clinical activity in EML4-ALK translocation-positive NSCLC

Wyeth identifies liver X receptor modulators for the treatment of lipoprotein disorders

MEK kinase inhibitors for cancer treatment presented by Genentech

LG Life Sciences claims glucokinase activators for the treatment of diabetes

Merck & Co. describe c-Met kinase inhibitors for cancer treatment

Novel alpha2-adrenoceptor ligands in early development at Allergan

Novel tyrosine hydroxylase inducers discovered by French investigators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...